Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2023-07-06 00:00:00 ET · period of report 2023-07-03 · accession 0001209191-23-041495 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-06 | 2023-07-03 | NTLA | Clark Eliana | EVP, Chief Technical Off | S - Sale | $40.51 | -360 | 45.1K | -0.8% | -$14.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-03 | S | D | 360 | $40.51 | 45,146 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.51 to $40.52, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 3, 2023 at each separate price. |